Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

BACKGROUND: For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which has also been suggested to be a useful treat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Beukhof, Carolien M., Brabander, Tessa, van Nederveen, Francien H., van Velthuysen, Marie-Louise F., de Rijke, Yolanda B., Hofland, Leo J., Franssen, Gaston J. H., Fröberg, Lideke A. C., Kam, Boen L. R., Visser, W. Edward, de Herder, Wouter W., Peeters, Robin P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6451300/
https://ncbi.nlm.nih.gov/pubmed/30953466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5540-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi